Supplies Still Limited More Than a Year After Monoclonal Antibodies Authorized for Treating COVID-19

Click here to read the full article.

Despite being the only authorized outpatient medical therapy for preventing the worsening of COVID-19 symptoms in high-risk patients, there remains no steady supply of monoclonal antibodies from the federal government a year after its approval for use by medical regulators.

Rolled out in the same month as the COVID-19 vaccines, monoclonal antibody therapies have not gotten the attention that vaccine treatments have after they were billed as the thing to get America out of the pandemic.

Even today, President Joe Biden continues to mostly focus on vaccinating children, providing boosters to every adult, and increase testing as part of his “new actions” to combat the COVID-19 pandemic during the winter.

Dr. Marc Siegel, a practicing internist and a professor of medicine at NYU’s Langone Medical Center, says vaccines alone cannot bring America out of the pandemic. More breakthrough cases are occurring with the Delta and Omicron variants, and hospitalizations are rising this winter.

Continue reading here.

Scroll down for comments and share what’s on your mind.

What do you think?

Leave a Reply

Your email address will not be published.

GIPHY App Key not set. Please check settings

Judge Gives FDA Just Over 8 Months to Produce Pfizer’s Safety Data

Mike Pompeo tells The Post how he lost 90 pounds in six months